|
|
|
|
|
|
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)
This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.
A Non-interventional Study to Prospectively Assess Baseline Status and Disease Progression in Male Children With X-Linked Adrenoleukodystrophy
This is a non-interventional, multi-center study that follows general principles of periodic assessment of X-ALD patients in routine practice. No study drug treatment will be given and no changes to patient treatment are necessary.
100 Clinical Results associated with NeuroVia, Inc.
0 Patents (Medical) associated with NeuroVia, Inc.
100 Deals associated with NeuroVia, Inc.
100 Translational Medicine associated with NeuroVia, Inc.